MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/eurheartj/ehad798

Медицинская библиотека · European heart journal · 2024

Oral anticoagulation after atrial fibrillation catheter ablation: benefits and risks.

Kanaoka Koshiro, Nishida Taku, Iwanaga Yoshitaka, Nakai Michikazu, Tonegawa-Kuji Reina, Nishioka Yuichi, Myojin Tomoya, Okada Katsuki, Noda Tatsuya, Kusano Kengo, Miyamoto Yoshihiro, Saito Yoshihiko, Imamura Tomoaki

Наблюдательное исследованиеСтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND AND AIMS: Few recent large-scale studies have evaluated the risks and benefits of continuing oral anticoagulant (OAC) therapy after catheter ablation (CA) for atrial fibrillation (AF). This study evaluated the status of continuation of OAC therapy and the association between continuation of OAC therapy and thromboembolic and bleeding events according to the CHADS2 score.

METHODS

This retrospective study included data from the Japanese nationwide administrative claims database of patients who underwent CA for AF between April 2014 and March 2021. Patients without AF recurrence assessed by administrative data of the treatment modalities were divided into two groups according to continuation of OAC therapy 6 months after the index CA. The primary outcomes were thromboembolism and major bleeding after a landmark period of 6 months. After inverse probability of treatment weighting analysis, the association between OAC continuation and outcomes was determined according to the CHADS2 score.

RESULTS

Among 231 374 patients included, 69.7%, 21.6%, and 8.7% had CHADS2 scores of ≤1, 2, and ≥3, respectively. Of these, 71% continued OAC therapy at 6 months. The OAC continuation rate was higher in the high CHADS2 score group than that in the low CHADS2 score group. Among all patients, 2451 patients (0.55 per 100 person-years) had thromboembolism and 2367 (0.53 per 100 person-years) had major bleeding. In the CHADS2 score ≤1 group, the hazard ratio of the continued OAC group was 0.86 [95% confidence interval (CI): 0.74-1.01, P = .06] for thromboembolism and was 1.51 (95% CI: 1.27-1.80, P < .001) for major bleeding. In the CHADS2 score ≥3 group, the hazard ratio of the continued OAC group was 0.61 (95% CI: 0.46-0.82, P = .001) for thromboembolism and was 1.05 (95% CI: 0.71-1.56, P = 0.81) for major bleeding.

CONCLUSIONS

This observational study suggests that the benefits and risks of continuing OAC therapy after CA for AF differ based on the patient's CHADS2 score. The risk of major bleeding due to OAC continuation seems to outweigh the risk reduction of thromboembolism in patients with lower thromboembolic risk.

Для цитирования: Kanaoka Koshiro, Nishida Taku, Iwanaga Yoshitaka, Nakai Michikazu, Tonegawa-Kuji Reina, Nishioka Yuichi, Myojin Tomoya, Okada Katsuki, Noda Tatsuya, Kusano Kengo, Miyamoto Yoshihiro, Saito Yoshihiko, Imamura Tomoaki. Oral anticoagulation after atrial fibrillation catheter ablation: benefits and risks.. European heart journal. 2024. DOI: 10.1093/eurheartj/ehad798.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.